Unresectable urothelial carcinoma

Nivolumab in combination with cisplatin and gemcitabine is approved by the USFDA for unresectable or metastatic urothelial carcinoma

March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin and gemcitabine as the initial treatment...
unresectable-urothelial-carcinoma

Scan the code

Tag: Unresectable urothelial carcinoma

Home / Unresectable urothelial carcinoma

Categories

Nivolumab in combination with cisplatin and gemcitabine is approved by the USFDA for unresectable or metastatic urothelial carcinoma

Information

Treatment

United States

India

Shanghai

Beijing

Hong Kong